全文获取类型
收费全文 | 1843篇 |
免费 | 79篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 165篇 |
妇产科学 | 76篇 |
基础医学 | 405篇 |
口腔科学 | 15篇 |
临床医学 | 175篇 |
内科学 | 292篇 |
皮肤病学 | 13篇 |
神经病学 | 49篇 |
特种医学 | 13篇 |
外科学 | 264篇 |
综合类 | 186篇 |
预防医学 | 157篇 |
眼科学 | 45篇 |
药学 | 82篇 |
中国医学 | 2篇 |
肿瘤学 | 24篇 |
出版年
2024年 | 1篇 |
2023年 | 23篇 |
2022年 | 33篇 |
2021年 | 58篇 |
2020年 | 46篇 |
2019年 | 57篇 |
2018年 | 51篇 |
2017年 | 44篇 |
2016年 | 62篇 |
2015年 | 64篇 |
2014年 | 95篇 |
2013年 | 101篇 |
2012年 | 77篇 |
2011年 | 106篇 |
2010年 | 85篇 |
2009年 | 96篇 |
2008年 | 113篇 |
2007年 | 79篇 |
2006年 | 110篇 |
2005年 | 88篇 |
2004年 | 91篇 |
2003年 | 68篇 |
2002年 | 51篇 |
2001年 | 39篇 |
2000年 | 46篇 |
1999年 | 32篇 |
1998年 | 28篇 |
1997年 | 24篇 |
1996年 | 19篇 |
1995年 | 21篇 |
1994年 | 21篇 |
1993年 | 21篇 |
1992年 | 25篇 |
1991年 | 12篇 |
1990年 | 15篇 |
1989年 | 20篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 9篇 |
1981年 | 6篇 |
1979年 | 3篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有1983条查询结果,搜索用时 31 毫秒
1.
肝移植术后巨细胞病毒性肺炎的临床特点和治疗方法 总被引:1,自引:0,他引:1
目的 探讨肝移植术后巨细胞病毒(CMV)性肺炎的临床特点和治疗方法。方法 回顾性分析2003年10月至2005年6月间施行肝移植的451例患者的临床资料,对肝移植术后CMV性肺炎的临床特点和治疗方法进行总结。结果 在451例患者中,发生CMV性肺炎7例,感染率为1.66%。CMV性肺炎的症状明显早于体征,7例患者均无明显诱因出现高热,约1周后逐渐出现干咳、气促、呼吸困难等;血氧饱和度降低,血气分析提示低氧血症;CMV pp65抗原检测均为阳性。CMV性肺炎患者采用更昔洛韦联合膦甲酸钠抗病毒治疗,同时采取停用免疫抑制剂、加用较大剂量的丙种球蛋白和适量的胸腺肽等的个体化免疫调节方案以及广谱抗生素等综合治疗方法,6例治愈,治愈率为85.7%。结论 CMV性肺炎的早期临床表现虽然缺乏特异性,但仍有规律可循,CMV pp65抗原检测法具有特异性和敏感性高的特点。采取联合抗病毒和个体化免疫调节等综合措施治疗CMV性肺炎效果确切。 相似文献
2.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients 总被引:1,自引:0,他引:1
A. Åsberg A. Humar H. Rollag A. G. Jardine H. Mouas M. D. Pescovitz D. Sgarabotto M. Tuncer I. L. Noronha A. Hartmann 《American journal of transplantation》2007,7(9):2106-2113
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study. 相似文献
3.
Nephrotic syndrome in a mother and her infant: relationship with cytomegalovirus infection 总被引:1,自引:0,他引:1
Marisa Giani Alberto Edefonti Beatrice Damiani Giuseppina Marra Daniela Colombo Giovanni Banfi Emilio Rivolta Erich H. Strøm Michael Mihatsch 《Pediatric nephrology (Berlin, Germany)》1996,10(1):73-75
This case report describes infantile nephrotic syndrome (NS) in a baby girl with a clinically severe cytomegalovirus (CMV) infection. Culture of the baby's urine was positive for CMV and IgM anti-CMV antibodies were detected. After an unsuccessful course of corticosteroids, gancyclovir treatment was started and a remission of cutaneous, pulmonary, and renal symptoms was achieved. As the mother also developed NS at the end of pregnancy, a common etiology could be postulated, although there were no signs of recent CMV infection in the mother, only anti-CMV IgG. The relationship between CMV infection and glomerular disease is still unclear: NS may represent another manifestation of CMV disease. 相似文献
4.
巨细胞病毒肝炎患儿血清细胞因子水平测定及其临床意义 总被引:4,自引:2,他引:2
目的 研究巨细胞病毒 (CMV)肝炎患儿血清干扰素 α(IFN α)、白细胞介素 8(IL 8)和肿瘤坏死因子 α(TNF α)水平的变化及其临床意义。方法 应用ELISA法检测 35例CMV肝炎患儿血清中上述三种细胞因子的含量 ,并对其两两之间进行了相关性分析。结果 CMV肝炎组患儿IFN α、IL 8、TNF α的含量分别为 (770 .3± 2 0 5 .4 )ng/L、(41.9± 2 2 .5 )ng/L和 (10 33.2± 388.5 )ng/L ,非常显著高于正常对照组 (P <0 .0 1)。相关性研究发现IFN α与TNF α呈显著正相关 (r =0 .35 6 ,P <0 .0 5 )。结论 血清细胞因子明显增高与CMV肝炎的病理变化和病损程度有着密切的联系 相似文献
5.
María de Oña Navarro Santiago Melón Susana Méndez Beatriz Iglesias Ana Palacio María J. Bernardo José L. Rodriguez-Lambert Ernesto Gómez 《Transplant international》2002,15(11):570-573
Ganciclovir (GCV) prophylaxis or pre-emptive therapy significantly reduce the rate of cytomegalovirus (CMV) disease and viremia, but increase the potential for emergence of ganciclovir-resistant CMV strains. The inhibitor concentration at 50% (IC(50)) of GCV from 156 CMV isolates from 59 renal or heart transplant recipients was calculated by means of a rapid phenotypic susceptibility assay. Twenty-seven strains were from 14 patients undergoing GCV therapy. The IC(50) was higher in patients under the prophylaxis regimen. One CMV strain, from a heart transplant recipient, became GCV-resistant after 1 month of therapy (IC(50)=13.7 micromol/l). These data, together with clinical and virological markers, suggested that a switch to foscarnet was necessary, and good evolution was observed. Thus, assay of CMV susceptibility to GCV could be helpful in clinical management. 相似文献
6.
目的:分析用血浆巨细胞病毒(cytomegalovirus,CMV)多聚酶链反应(plymerase chain reaction,PCR)检测结果指导抗CMV干预性治疗的临床意义。方法:1999年8月至2001年7月行异基因造血干细胞移植(hematopoietic stem cell transplantation,HSCT)的所有患者自预处理开始,常规用PCR法检测血浆的CMV-DNA(采用华美公司生产的巨细胞病毒4℃ PCR检测试剂盒),每周1次。其中尚无CMV病的临床表现而检测到血浆CMV阳性的患者89例。随机选取52例阳性患者给予干预性治疗。将上述89例患者分为3组(分别为停止治疗时血浆CMV-PCR转阴组、停止治疗时未转阴组、血浆CMV阳性未治疗组)比较各组CMV病的发生率。CMV病的发生率采用Kaplan-Meier曲线表示,曲线间的比较用Log-Rank(曲线无交叉)或Breslow(曲线交叉)检验,某时点率的比较采用RXC列联表或χ^2检验。结果:100d内CMV病的发生率,在治疗后血浆CMV-PCR由阳性转为阴性组为10.26%,治疗结束时血浆CMV-PCR仍为阳性组为66.67%,血浆CMV-PCR阳性未治疗组为36.24%(P=0.0000)。上述3组中任两组移植后100d CMV病的发生率差异均有显著性。移植后1年时上述3例CMV病累积发生率分别为30.65%、75.00%、42.95%(P=0.0009),治疗未转阴组与治疗转阴组和阳性未治疗组相比,CMV病的发生率明显升高。结论:血浆CMV-PCR检测结果用来指导干预性治疗有一定临床意义。干预性治疗后血浆CMV-DNA仍未转阴者,应考虑换药或联合用药治疗。 相似文献
7.
The antiviral agent foscarnet has long been used in our unit to treat cytomegalovirus (CMV) infections in renal transplant
patients. The clinical effect has been convincing and, apart from changes in serum calcium levels, very few side effects have
been noted. We have, however, observed a nephrotoxic reaction in a series of patients with initially good renal function who
therefore received high doses of foscarnet. Transplant biopsies performed in five of those patients revealed degenerative
changes in the tubular epithelial cells as well as tubular calcium deposits and an infiltration of the interstitium by mixed
mononuclear and polymorphonuclear leucocytes. Renal insufficiency was accompanied by high fever. After withdrawal of the drug,
the temperature rapidly normalized, whereas serum creatinine continued to rise for about 3 days and then fell back towards
previous levels. We conclude that transplant biopsies are of great value in distinguishing between a foscarnet nephrotoxic
effect and CMV nephritis, various forms of rejection, and other causes of impaired renal function. 相似文献
8.
目的 探讨实质器官移植术后血浆中白介素18(IL-18)、白介素10(IL-10)、白介素4(IL-4)水平的检测在人巨细胞病毒(HCMV)感染中的意义。方法 对24例实质器官移植受者,用免疫组化法监测HCMV抗原血症。然后采用ELISA法测定血浆中IL-18、IL-10及IL-4的水平。结果 HCMV抗原阳性组IL-18的水平高于阴性组(P<0.01),IL-10及IL-4的水平低于阴性组(均P<0.05)。结论 血浆IL-18的水平可作为预测移植患者HCMV感染的一个有效指标,IL-10及IL-4的水平则可作为患者HCMV感染后体内免疫抑制程度的监测指标之一。 相似文献
9.
Interactions Between Cytomegalovirus, Human Herpesvirus-6, and the Recurrence of Hepatitis C After Liver Transplantation 总被引:1,自引:0,他引:1
Atul Humar Deepali Kumar Janet Raboud Angela M. Caliendo George Moussa Gary Levy Tony Mazzulli 《American journal of transplantation》2002,2(5):461-466
Recurrence of hepatitis C (HCV) following liver transplantation is common. Herpesvirus reactivation following transplant may have an immunomodulatory effect resulting in increased HCV replication. We studied whether cytomegalovirus (CMV) and human herpesvirus-6 (HHV-6) may be associated with HCV recurrence and viral load after transplant. We prospectively followed 66 HCV liver-transplant recipients with serial viral load testing for CMV and HHV-6. Infection and viral load were correlated with the development of biopsy-proven HCV recurrence and HCV viral loads. Histologic recurrence of HCV occurred in 41/66 (62.1%) patients. In the primary analysis, CMV infection and disease, and HHV-6 infection were not associated with HCV recurrence. Peak CMV and HHV-6 viral loads were not significantly different in patients with and without recurrence. No correlation was observed between HCV viral loads at 1 and 3 months post-transplant and peak HHV-6 or CMV viral loads. In a subgroup analysis, HHV-6 infection was associated with the development of more severe recurrence (hepatitis and/or fibrosis score > or = 2) (p = 0.01). Also, fibrosis scores at last follow up were higher in patients with CMV disease (1.67 vs. 0.56; p = 0.016) and in patients with HHV-6 infection (1.18 vs. 0.55; p = 0.031). In conclusion, HHV-6 and CMV infection and viral load were not associated with increased overall rates of HCV recurrence or HCV viral load after liver transplantation but may be associated with more severe forms of recurrence. 相似文献
10.
Abstract We previously demonstrated that cytomegalovirus (CMV) infection enhanced perivascular inflammation in rat aortic allografts. In this study, we investigated the relationship between the CMV infection load and the magnitude of perivasculitis (chronic rejection) in aortic transplants. Rats received or-thotopic abdominal aortic grafts, different degrees of total body irradiation (TBI) for immunosuppres-sion and CMV inoculation. The spleens of the rats receiving 5 Gy of TBI contained more infectious virus and viral antigens than those of rats receiving 3 Gy of TBI or no TBI. Although the number of inflammatory cells infiltrating the perivascular area was decreased after TBI, CMV infection resulted in increased perivasculitis in rats that received 5 Gy of TBI as compared to non-infected animals. This virus-induced effect was characterized predominantly by an increased T-cell infiltration, including CD4 and CD8 T-cells. It is concluded that an enhanced systemic CMV infection during severe immunosuppressive therapy can accelerate the development of chronic rejection, which seems to be mediated mainly by T-cells. 相似文献